Bitcoin News Today: Bitcoin’s Liquidity Dynamics: Small Investors Surpass Large Holders in Accumulation
- Bitcoin whales (1,000–100,000 BTC) sold 112,000 coins over 60 days, but smaller holders and short-term whales offset this with increased accumulation. - Long-term holders (>10 years) remain net buyers, while mid-cycle whales (3–5 years active) dominate selling, reflecting a generational shift in on-chain behavior. - Price dips below $100,000 coincided with rising 1,000+ BTC holder counts—a pattern seen before 2024’s ETF-driven peak—suggesting potential accumulation ahead of a rebound. - Market observers
Large Bitcoin holders are adjusting their on-chain tactics, with recent data pointing to a subtle change in the behavior of major investors. In the last two months, wallets containing between 1,000 and 10,000
Looking at the bigger picture, whales holding 10,000 to 100,000 BTC have
Examining activity by holding period reveals more complexity. Whales who were active between 6 and 24 months ago have been net sellers, while those holding coins for over ten years continue to accumulate. For example, the net 30-day change for holders last active 6–24 months was -202,674 BTC,
Recent declines in price have
Market observers see these developments as a possible turning point. While long-term holders remain steady, short-term whales and smaller investors are positioning for a potential recovery, indicating a shift from selling to accumulating. Whether this marks the start of a lasting uptrend or just a brief pause will hinge on broader economic factors and upcoming regulatory changes.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
XRP News Today: SEC Approves Altcoin ETFs, Boosting Institutional Investment in Cryptocurrency
- SEC approves multiple XRP/DOGE ETFs from 21Shares, Franklin Templeton, and Grayscale, signaling growing institutional acceptance of altcoins. - 21Shares' TOXR ETF gains automatic approval via CME CF XRP-Dollar tracking, with Coinbase and BNY Mellon handling custody/admin functions. - Franklin Templeton's XRP Trust removes restrictive clauses to accelerate listing, offering regulated exposure without custody risks from ledger forks. - Grayscale expands crypto offerings with XRP/DOGE ETFs on NYSE, joining

Germany's Solar Turning Point: Spotlight on Legislation, Infrastructure, and Ideological Differences
- Germany's SolarPlus Forum 2025 emphasized legislative clarity, funding innovation, and cross-sector collaboration to accelerate solar adoption amid evolving energy policies. - Outdated regulations and permitting hurdles were highlighted as barriers, with calls to align Bundestag reforms with market demands like gas surcharge removal by 2026. - Cement industry growth (5.7% CAGR) and green innovations support infrastructure needs, though energy cost volatility and compliance challenges persist. - Internati

Polkadot Latest Updates: ECB Raises Concerns: Cryptocurrency and Stock Market Downturns Resemble Dot-Com Bubble Threats
- ECB warns U.S. equity/crypto corrections threaten stability, urging central banks to retain rate-cut flexibility amid market volatility. - JPMorgan links crypto ETF outflows to retail investor behavior, noting $4B November sales contrast with $96B equity ETF inflows. - U.S. Treasury downplays recession risks, citing 2026 growth optimism despite shutdown impacts and services-driven inflation. - MSCI highlights tech valuation risks akin to dot-com era, while DeFi faces $12B liquidity crisis with 95% capita

Novartis Increases 2030 Growth Projections Despite Analysts' Concerns About Patent Threats
- Novartis raised 2030 sales growth targets to 5-6% annually, driven by high peak sales expectations for oncology drugs Kisqali and Scemblix. - CEO Vas Narasimhan highlighted eight de-risked drugs with $3-10B peak potential, but analysts warned of patent expirations and uncertain pipeline progress beyond 2030. - Shares rose 0.5% post-announcement, while Exact Sciences surged 17% on its $105/share acquisition by Abbott and Samsung Biologics saw a 71% valuation re-rating after spin-off. - J.P. Morgan caution
